Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Novel Agents Under Investigation for AML

January 28th 2020

Immune Checkpoint Inhibitors for AML

January 28th 2020

Gemtuzumab Ozogamicin for CD33+ AML and APL

January 28th 2020

The Future Landscape of Follicular Lymphoma Treatment

January 28th 2020

Differentiation Syndrome and IDH1/2 Inhibitors

January 28th 2020

IDH1/2 Inhibitors in AML

January 28th 2020

Phase Ib Polatuzumab Vedotin Trial

January 28th 2020

Relapsed/Refractory FLT3-Mutated AML

January 28th 2020

The Phase III GADOLIN Trial

January 28th 2020

Second-Generation FLT3 Inhibitors for AML

January 28th 2020

Previously Untreated FL: Obinutuzumab Plus Lenalidomide

January 28th 2020

The Phase II EZH2 Inhibitor Trial

January 28th 2020

Previously Untreated FLT3-Mutated AML

January 28th 2020

CPX-351 for Secondary AML

January 28th 2020

Sequencing Strategies for Later-Line Therapy

January 28th 2020

Venetoclax-Based Chemotherapy Combinations in AML

January 28th 2020

The DYNAMO Later-Line Regimen

January 28th 2020

Managing Venetoclax-Associated Toxicity in AML

January 28th 2020

Treatment Options After Second-Line Relapse

January 28th 2020

Venetoclax-Based Regimens for Unfit Patients with AML

January 28th 2020